Maze Therapeutics, Inc. (MAZE) vs Novavax, Inc. (NVAX)
- Maze Therapeutics, Inc. MAZE 32.01 −1.75%
- Novavax, Inc. NVAX 10.00 −9.17%
Maze Therapeutics, Inc. and Novavax, Inc. are both Biotechnology companies. Maze Therapeutics, Inc. and Novavax, Inc. are of similar size ($1.8B and $1.8B). Maze Therapeutics, Inc. has the higher net margin (0.00% vs −59.9%) and the lower return on invested capital (−112.4% vs 0.00%). Across the 12 metrics below, Novavax, Inc. leads on 7 and Maze Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | MAZE | NVAX | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 78.60% | 65.77% |
| Operating margin | 0.00% | (56.58%) | 0.00% |
| Net margin | 0.00% | (59.87%) | 0.00% |
| Free cash flow margin | 0.00% | (10.20%) | 0.00% |
| Return on equity | (37.35%) | 323.66% | (54.09%) |
| Return on assets | (31.99%) | (21.62%) | (47.78%) |
| Return on invested capital | (112.36%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack